Rheumatic Myocarditis Treatment Market Size & Share, by Age Group (Under 5 years, 5-15 years, 15-40 years, Above 40 years); Diagnosis (Blood Tests, Echocardiogram, Electrocardiogram); Treatment (Anticonvulsant Medications, Surgery); End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3325
  • Published Date: Mar 21, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2035

Rheumatic Myocarditis Treatment Market size is estimated to cross USD 2 billion by the end of 2035, growing at a CAGR of 5% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of rheumatic myocarditis treatment was over USD 1 billion. The major factor attributed to market growth is the rising incidence of rheumatic heart disease among the global population and the increasing prevalence of rheumatic fever which is generating the need for rheumatic myocarditis treatment during the forecast period. According to a recently published report in 2021, it is estimated that around 34 million people around the world have rheumatic heart disease. Moreover, it is being calculated that 300,000 to 500,000 new cases of rheumatic fever are diagnosed every year worldwide.

In addition to the aforementioned factors, the rapid advancement in drugs and biotechnology is estimated to bring in lucrative growth opportunities for the expansion of the global rheumatic myocarditis treatment. Apart from this, the escalation in cases of rheumatic fever, and strep throat along with the growing prevalence of inflammatory diseases around the world is anticipated to create a positive outlook for market growth during the forecast period. Furthermore, another factor that is estimated to drive the rising focus of the governments of different nations to enhance healthcare facilities and medical offerings. Also, the rising cases of chronic diseases and cardiovascular disorders which lead to rheumatic myocarditis are forecasted to generate a high demand for rheumatic myocarditis treatment which is estimated to subsequently increase the market size in the upcoming years.


Rheumatic Myocarditis Treatment Market
Get more information on this report: Request Free Sample PDF

Rheumatic Myocarditis Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Rapid Rise in the Number of Cases of Rheumatic Fever – In the recent period, there has been a global burden on the economy owing to the increasing rheumatic fever around the world which is developed as a result of strep throat. Treating such autoimmune diseases is estimated to increase the utilization rate of rheumatic myocarditis treatment, especially in low and middle-income countries. The report published by the Centers for Disease Control and Prevention (CDC) estimated that around 470,000 new cases of acute rheumatic fever are diagnosed every year around the globe.

  • Rising Incidences of Cardiovascular Diseases Among the Global Population – More and more people have been diagnosed with cardiovascular diseases in the past years as a result of shifting towards a sedentary lifestyle and consumption of unhealthy food items. The rising cases of cardiovascular diseases could weaken the heart and deteriorate the functioning of heart values which could lead to rheumatic myocarditis. Thus, the escalation in cardiovascular diseases is estimated to bring favorable opportunities for market expansion in the forecast period. The World Health Organization (WHO) stated that cardiovascular diseases are considered to be a major cause of deaths occurring at the global level, taking almost 17.9 million lives each year.

  • Lack of Basic Sanitation Facilities – Even though the economies are growing, a major portion of people are living without basic sanitation facilities. Living under unhygienic conditions is estimated to increase the occurrence of rheumatic fever which ultimately leads to rheumatic heart disease. Therefore, the absence of fundamental facilities for hygiene is estimated to generate the need for rheumatic myocarditis treatment during the forecast period to treat patients. The Centers for Disease Control and Prevention (CDC) stated that around 3.6 billion people around the world lack access to safely managed sanitation in their homes and around 2 billion people worldwide lack basic safe drinking water services.

  • Growing Percentage of Elderly People in the World – Old people have weakened bodies and deteriorating body organs which makes them prone to rheumatic myocarditis. Thus, with the burgeoning population, it is estimated that the demand for rheumatic myocarditis treatment is expected to grow during the forecast period. The data released by the Department of Economic and Social Affairs, United Nations revealed that in 2019, approximately 703 million people of age 65 and above were present. This figure is estimated to double by 2050 to reach almost 2.1 billion worldwide.

  • High Amount of Investment in Developing the Healthcare Sector – Key players operating in the market along with the governments of different countries are focusing on developing novel medicinal products and advanced medical items for rheumatic myocarditis treatment. As a result, a high amount is being invested in the healthcare sector to aid research and development activities. For instance, investment in medical and health research and development (R&D) in the United States (U.S.) increased by 11% to around USD 245 billion in 2020 from previous years.

Challenges

  • Risks and Complications Associated with Surgical Procedures
  • High Costs Associated with Rheumatic Myocarditis Treatment – As rheumatic myocarditis is considered to be a rare disease; the treatment procedure requires technologically developed medical products which are generally of high costs. This leads to a surge in the overall treatment of rheumatic myocarditis. Hence, this factor is anticipated to lower the adoption rate of rheumatic myocarditis treatment and hamper market growth during the forecast period.
  • Less Awareness Level About the Disease and its Treatment 

Rheumatic Myocarditis Treatment Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~5%

Base Year Market Size (2022)

~ USD 1 Billion

Forecast Year Market Size (2035)

~ USD 2 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Rheumatic Myocarditis Treatment Segmentation

Diagnosis (Blood Tests, Echocardiogram, Electrocardiogram)

The global rheumatic myocarditis treatment market is segmented and analyzed for demand and supply by diagnosis into blood tests, echocardiograms, electrocardiograms, and others. Out of these, the electrocardiograms segment is estimated to gain the largest market share of about ~41% in the year 2035. The major factor attributed to segment growth is the growing advantages of electrocardiograms and the usage of electrocardiograms for the detection of fatal diseases such as rheumatic myocarditis. As per a report published in the National Library of Medicine in 2022, it has been calculated that almost 300 million electrocardiograms are conducted every year across the world. Also, the availability of advanced medical products for the proper functioning of electrocardiograms is anticipated to create a positive outlook for significant revenue generation and segment growth.

End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare)

The global rheumatic myocarditis treatment market is also segmented and analyzed for demand and supply by end-user into hospitals, ambulatory surgical centers, specialty clinics, homecare, and others. Amongst these segments, the hospital segment is expected to garner a significant share of around ~35% in the year 2035 with a significant CAGR value. The major factor that is attributed to segment growth is the increasing development of hospital infrastructure across the world and the availability of hospitals in every region that helps in aiding the treatment of rheumatic myocarditis in hospital settings. For instance, there were over 8,000 hospitals in Japan as of 2020. Korea, by contrast, had about 4,000 hospitals. In addition, there were more than 6000 hospitals in the United States. Also, the rising preference of the global population to get treated in hospitals for rheumatic myocarditis owing to the availability of specialized doctors, enhanced infrastructure, and technologically-advanced medical products for treatment procedures. 

Our in-depth analysis of the global market includes the following segments:

             By Age Group

  • Under 5 years
  • 5-15 years
  • 15-40 years
  • Above 40 years

            By Diagnosis

  • Blood Tests
  • Echocardiogram
  • Electrocardiogram
  • Others

           Treatment

  • Anticonvulsant Medications
  • Surgery
  • Others

            By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Homecare
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Rheumatic Myocarditis Treatment Industry - Regional Synopsis

North American Market Forecast

The North American rheumatic myocarditis treatment market, amongst the market in all the other regions, is projected to hold the largest market share of about ~35% by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of rheumatic fever and subsequently rheumatic myocarditis amongst several people, backed by rising awareness about the disease among people and high healthcare expenditure for treatment procedures. For instance, the Centers for Medicare and Medicaid Services stated that the National Health Expenditure (NHE) of Americans grew almost 2.7% to reach USD 4.3 trillion which is also equivalent to USD 12,914 per person in 2021. It has also been calculated that national healthcare expenditure accounted for approximately 18.3% of the nation’s total Gross Domestic Product (GDP). Further, the presence of a strong healthcare network in the region, along with the availability of supportive advanced therapy medicinal products  to develop efficient treatment options, are also anticipated to contribute to market growth in the region. In addition, the high expenditure for expanding the healthcare industry and rising initiatives by the government to increase the awareness level about the disease in the region are also anticipated to spur market growth during the forecast period.

APAC Market Statistics

The Asia Pacific rheumatic myocarditis treatment market, amongst the market in all the other regions, is projected to hold the second largest share of about ~24% during the forecast period. The major factor for market growth is the rising pool of patients diagnosed with chronic diseases which leads to rheumatic fever and rheumatic myocarditis. Also, the presence of biobanking and e-prescribing in the region is estimated to bring favorable options for the adoption of rheumatic myocarditis treatment among the people living in the region. Furthermore, the presence of major key players in the region and their increased active participation in developing novel techniques for rheumatic myocarditis treatment is also estimated to bring lucrative growth opportunities for market growth during the forecast period.

Europe Market Forecast

Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The rising initiatives by the major key players and the European government to increase the awareness level of the disease and its treatment coupled with the rising shift of people towards health and fitness are considered to be major factors for market expansion in the region in the upcoming years.

Research Nester
Rheumatic Myocarditis Treatment Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Rheumatic Myocarditis Treatment Landscape

top-features-companies
    • Siemens Healthcare GmbH
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • CryoLife Inc.
    • Edwards Lifesciences Corporation
    • Neovasc Inc.
    • HighLife SAS
    • Abbott Laboratories
    • Sanofi-aventis Groupe
    • Pfizer Inc.
    • Boston Scientific Corporation
    • Medtronic PLC 

In-the-news

In The News

  • Siemens Healthcare GmbH has launched the technologically-advanced multidisciplinary angiography system ARTIS icono. With its development, the company is expected to cater to different needs of cardiovascular interventions, interventional radiology, neuroradiology, and vascular interventions.

  • Pfizer Inc. has finally acquired Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company that is dedicated to the discovery, development, and delivery of life-changing treatments for patients diagnosed with sickle cell disease (SCD). The acquisition is anticipated to broaden the offerings provided by the company.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3325
  • Published Date: Mar 21, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising prevalence of rheumatic fever and the growing availability of over-the-counter drugs are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2035.

Risks and complications associated with surgery coupled with high costs associated with the treatment and less awareness level about the disease are estimated to be the growth hindering factors for the market expansion.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Siemens Healthcare GmbH, CryoLife Inc., Edwards Lifesciences Corporation, Neovasc Inc., HighLife SAS, Abbott Laboratories, Sanofi-aventis Groupe, Pfizer Inc., Boston Scientific Corporation, Medtronic PLC, and other key players.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by age group, diagnosis, treatment, end-user, and by region.

The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Rheumatic Myocarditis Treatment Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying